Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone

 
• By Jessica Merrill
  
Subcutaneous injection
Teva hopes to bring a subcutaneous risperidone to market • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D